The STOP GAMES Act of 2026 aims to streamline the approval process for affordable medicines by addressing petitions intended to delay drug approvals.

The STOP GAMES Act of 2026 amends the Federal Food, Drug, and Cosmetic Act to expedite the approval of affordable medicines. It clarifies the process for denying petitions submitted with the primary purpose of delaying drug approvals. The Secretary of Health and Human Services can deny such petitions at any point and must refer them to the Federal Trade Commission. The Act also mandates the Secretary to issue guidance on factors used to determine if a petition aims to delay approval. Additionally, it modifies the timelines for petition submissions and civil actions related to drug approvals.

The STOP GAMES Act of 2026 aims to streamline the approval process for affordable medicines by addressing petitions intended to delay drug approvals.

The STOP GAMES Act of 2026 amends the Federal Food, Drug, and Cosmetic Act to expedite the approval of affordable medicines. It clarifies the process for denying petitions submitted with the primary purpose of delaying drug approvals. The Secretary of Health and Human Services can deny such petitions at any point and must refer them to the Federal Trade Commission. The Act also mandates the Secretary to issue guidance on factors used to determine if a petition aims to delay approval. Additionally, it modifies the timelines for petition submissions and civil actions related to drug approvals.